Dr. Ajay Tejwani, MD

Dr. Tejwani practices at The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System.

Dr. Tejwani's NPI, 1023278439, was assigned on June 10, 2008. Dr. Tejwani graduated from Tulane University School of Medicine in 2008. Dr. Tejwani holds Kansas license 04-36399.

Dr. Tejwani's primary practice is The University of Kansas Hospital, at 4000 Cambridge Street, Kansas City, KS 66160 in Wyandotte County. The practice phone is (913) 588-5000.

Dr. Tejwani's primary practice is The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System. Dr. Tejwani is also affiliated with NKC Health Hospital. The medical group on file is Kansas University Physicians. Dmand AI also links Dr. Tejwani to 2 more hospitals, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tejwani practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Tejwani's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Tejwani is licensed in Kansas.

CMS data shows 1,392 Medicare services from Dr. Tejwani across 16 procedure codes in 2024, for 185 Medicare patients. Medicare paid $103,602 for them.

CMS counts 185 Medicare patients who saw Dr. Tejwani in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tejwani's median patient age at 74, with 51% women.

In 2024, Dr. Tejwani wrote 187 Medicare Part D claims for 60 patients. 96% of them were for generic drugs. CMS names the drug for 89 of them, across 3 drugs with 11 or more claims each, at $1,941 in total drug cost. In 2023, CMS named 62 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Tejwani for performance year 2024, reported through an alternative payment model (APM). Dr. Tejwani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tejwani as offering telehealth.

Dmand AI links 8 papers to Dr. Tejwani, published from 2012 to 2021. 2012 was the busiest year, with 2. Dr. Tejwani's most frequent co-authors are Hani Lamei Ashamalla, MD, Amir Lavaf, MD and Bahaa El Sayed Mokhtar, MD.

Dmand AI links Dr. Tejwani to 2 clinical trials. 2 are still active or recruiting. NRG Oncology sponsors the most, 2.

CMS Open Payments shows 47 general payments to Dr. Tejwani from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Medtronic, Inc. paid the most, $187.

Dr. Tejwani graduated from Tulane University School of Medicine in 2008.